Lupin gets US FDA approval to market generic diabetes drug in the US
The Mumbai-based company has received a tentative approval from the USFDA for its Empagliflozin tablets
 "Lupin gets US FDA approval to market generic diabetes drug in the US")
premium
Drug maker Lupin on Tuesday said it has received approval from the US health regulator to market a generic diabetes drug in America.
The Mumbai-based company has received a tentative approval from the US Food and Drug Administration (USFDA) for its Empagliflozin tablets, in strengths of 10 mg and 25 mg, Lupin said in a statement.
The product is a generic version of Boehringer Ingelheim Pharmaceuticals, Inc's Jardiance tablets which are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
As per IQVIA MAT March 2020 data, the drug had an annual sales of around $4,368 million in the US.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%